CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G1Z2
- Cross Cancer Institute
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H2Y9
- Dalhousie University
-
-
Ontario
-
Toronto, Ontario, Canada, M5J2M9
- Princess Margaret Hospital
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V2H1
- Hospital Charles Lemoyne
-
Montreal, Quebec, Canada, PQH2W1S6
- McGill University
-
-
-
-
Alabama
-
Hoover, Alabama, United States, 35216
- Clinical Research Consultants, Inc.
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
Los Angeles, California, United States, 90095
- UCLA School of Medicine
-
San Francisco, California, United States, 94143
- UCSF California
-
Stanford, California, United States, 94305-5112
- Stanford University Medical Center, Division of Hematology
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University School Of Medicine
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic- Jacksonville
-
Miami, Florida, United States, 33136
- University of Miami
-
Sarasota, Florida, United States, 34239
- Oncology Hematology Consultants
-
Tampa, Florida, United States, 33612-9497
- H Lee Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Augusta, Georgia, United States, 30912-3125
- Medical College of Georgia
-
-
Illinois
-
Chicago, Illinois, United States, 60611-2927
- Northwestern University Med Ctr
-
Chicago, Illinois, United States, 60612-3824
- Rush Cancer Institute Section of Hematology
-
Maywood, Illinois, United States, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202-5254
- Indiana Cancer Research Institute
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospital Clinic
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70121
- Ocshner Clinical Foundation
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Johns Hopkins Medicine Department of Oncology
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University Of Michigan Comprehensive Cancer Center
-
Detroit, Michigan, United States, 48201
- Karmanos Cancer Institute
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine- Sherman Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
Buffalo, New York, United States, 14263
- Roswell Park Cancer Institute
-
New York, New York, United States, 10021
- New York Presbyterian Hospital
-
New York, New York, United States, 10011
- St. Vincent's Comprehensive Cancer Center
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
The Bronx, New York, United States, 10466
- MBCCOP Our Lady of Mercy Cancer Center New York Medical College
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, United States, 27157-1023
- Wake Forest University School of Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Myeloma Program
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Oregon
-
Portland, Oregon, United States, 97227
- Kaiser Permanente Northwest Region Center for Health Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Cancer Center
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Medical University Of SC
-
Charleston, South Carolina, United States, 29403
- Charleston Hematology/Oncology P.A.
-
West Columbia, South Carolina, United States, 29169
- South Carolina Oncology Group
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203-1632
- Sarah Cannon Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030-4009
- MD Anderson Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226-3522
- Froedtert Hospital/BMT Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Prior or current diagnosis Durie-Salmon stage II or III multiple myeloma.
- No more than 3 previous anti-myeloma regimens
- No high-dose dexamethasone (total monthly dose of dexamethasone greater than 200 mg) within 6 months of study randomization.
- Measurable levels of myeloma paraprotein in serum or urine (24-hour collection sample).
Exclusion Criteria:
- Prior development of disease progression during high-dose dexamethasone containing therapy.
- Laboratory abnormalities: Absolute neutrophil count less than 1,000 cells/mm cubed
- Laboratory abnormalities: Platelet count less than 75,000/mm cubed
- Laboratory abnormalities: Serum creatinine greater than 2.5 mg/dL
- Laboratory abnormalities: Serum glutamic oxaloacetic transaminase (SGOT, aspartate transaminase [AST]) or serum glutamic pyruvic transaminase (SGPT, alanine transaminase [ALT])greater than 3.0 x upper limit of normal
- Laboratory abnormalities: Serum total bilirubin greater than 2.0 mg/dL
- Prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for greater than or equal to 5 years.
- Known hypersensitivity to thalidomide or dexamethasone.
- Development of a desquamating rash while taking thalidomide.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: CC-5013/Dex
CC-5013 (lenalidomide) plus oral high-dose dexamethasone
|
Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
Other Names:
Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy.
Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
Other Names:
|
|
Experimental: Placebo/Dex
Placebo, identical in appearance to CC-5013 (lenalidomide), plus oral high-dose dexamethasone
|
Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy.
Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Tumor Progression (TTP)
Time Frame: 60 weeks (median Time To Progression of CC-5013/Dex treatment group)
|
Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et.
al., Br J Haematol 1998; 102:1115-1123.
|
60 weeks (median Time To Progression of CC-5013/Dex treatment group)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: 170 weeks (median overall survival of CC-5013/Dex treatment group)
|
Overall survival was calculated as the time from randomization to death from any cause.
|
170 weeks (median overall survival of CC-5013/Dex treatment group)
|
|
Myeloma Response
Time Frame: Up to Unblinding (07 Jun 2005)
|
The overall confirmed response that was maintained for ≥6 weeks.
Complete Response (CR):Disappearance of monoclonal paraprotein.
Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion.
Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion.
Stable Disease (SD):Criteria for PR or PD not met.
Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas.
Progressive Disease (PD):Disease worsens.
|
Up to Unblinding (07 Jun 2005)
|
|
Time to First Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status Scale (Best Score=0, Fully Active, Able to Carry on All Pre-disease Performance Without Restriction; Worst Score=5, Dead.)
Time Frame: 30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)
|
The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization.
|
30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007 Nov 22;357(21):2133-42. doi: 10.1056/NEJMoa070596.
- San-Miguel JF, Dimopoulos MA, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):38-43. doi: 10.3816/CLML.2010.n.120.
- Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, Dimopoulos MA, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. J Clin Oncol. 2010 Jan 1;28(1):132-5. doi: 10.1200/JCO.2009.23.0169. Epub 2009 Nov 9.
- Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood. 2008 Dec 1;112(12):4445-51. doi: 10.1182/blood-2008-02-141614. Epub 2008 Sep 17.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Dexamethasone
- Lenalidomide
Other Study ID Numbers
Other Study ID Numbers
- CC-5013-MM-009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.